FDA Approves First Cell Therapy for Solid Tumors, Marking a Significant Milestone In a groundbreaking development, the U.S. Food and...
Repotrectinib, a promising targeted therapy, has shown significant tumor reduction in patients with ROS1-positive non-small cell lung cancer (NSCLC). This...
Using Microrobots Controlled by a Magnetic Field for the Treatment of Liver Cancer Liver cancer is a serious and potentially...
Potential for cancer treatment demonstrated by metal-free graphene quantum dots Graphene, a two-dimensional material made up of a single layer...
Breast cancer is one of the most common types of cancer affecting women worldwide. According to the World Health Organization...
Immunotherapy Drug Makes Groundbreaking Progress in First Trial in Fifty Years In a significant breakthrough for cancer treatment, a new...
Dispelling the Top 5 Misconceptions about Cannabis: Debunking Reefer Madness Myths Cannabis, also known as marijuana, has been a topic...
Dispelling the Top 5 False Myths about Cannabis: Insights from Marijuana Myth Busters Cannabis, also known as marijuana, has been...
When Should You Seek Medical Attention for a Rash? A rash is a common skin condition that can occur due...
Phase 3 Trials of Revolutionary Cancer Vaccine Near Completion with Minimal Side Effects Cancer has long been one of the...
The Role of Genome Instability in Trisomy 21-Associated Myeloid Malignancies: A Study on Leukemia Introduction: Trisomy 21, also known as...
The Food and Drug Administration (FDA) has recently approved a groundbreaking drug called Balversa (erdafitinib) for the treatment of FGFR3+...
Successful Treatment of Multiple Myeloma in a Patient Following Hepatitis Treatment Multiple myeloma is a type of cancer that affects...
Novocure, a global oncology company specializing in the development of innovative cancer therapies, has recently submitted a Premarket Approval (PMA)...
NICE Issues Recommendation for Groundbreaking Breast Cancer Medication Breast cancer is one of the most common types of cancer affecting...
